Neuroconcise.co

NeuroCONCISE operates at the intersection of wearable medical devices, EEG research tools, digital health, and brain-computer interfaces. Its differentiation is an integrated hardware-software approach: FlexEEG combines configurable eight-channel EEG hardware, FlexStar wet or dry electrodes, wireless transmission, wireless charging, cloud connectivity, and developer APIs for Java, C#, C++, Python, and MATLAB. The ability to embed the system into hats and virtual-reality headwear gives it a form-factor emphasis that is less typical of conventional laboratory EEG equipment. The company also targets a broad application set, from clinical research and rehabilitation to neurofeedback, gaming, sport, and recreation. Against larger established neurotechnology and EEG vendors, NeuroCONCISE appears more focused on flexible, wearable, developer-accessible systems than on a broad hospital-device portfolio. Its small disclosed team and limited recent public activity suggest an early-stage specialist position rather than a scaled market leader.

NeuroCONCISE’s trajectory shows an early research-to-commercialization path, but limited evidence of acceleration after 2019. The company was founded in 2016 and received non-equity assistance that year, followed by a $172,886 seed round on Jan 1, 2017 and a further $105,679 seed round on Mar 26, 2019. Combined disclosed funding totals $278,565 across three rounds, including the non-equity assistance entry. The financing supported development of a platform that connects flexible EEG hardware with AI-enabled analysis, cloud services, and brain-computer interface functionality. Product breadth has expanded beyond a single headset concept: FlexEEG, FlexStar electrodes, FlexMI and FlexV montage configurations, NeuroPrecise software, wireless connectivity, and developer integrations address research and applied-use scenarios. The current employee indicator is one to ten people, with Damien Coyle listed as the only featured current position.